Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes

JV Aredo, SK Padda, CA Kunder, SS Han, JW Neal… - Lung Cancer, 2019 - Elsevier
Objectives Concurrent genetic mutations are prevalent in KRAS-mutant non-small cell lung
cancer (NSCLC) and may differentially influence patient outcomes. We sought to …
被引用次数：117 相关文章

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.

JV Aredo, SK Padda, CA Kunder, SS Han… - Lung Cancer …, 2019 - europepmc.org
Objectives Concurrent genetic mutations are prevalent in KRAS-mutant non-small cell lung
cancer (NSCLC) and may differentially influence patient outcomes. We sought to …

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes

JV Aredo, SK Padda, CA Kunder, SS Han… - Lung …, 2019 - lungcancerjournal.info
Objectives Concurrent genetic mutations are prevalent in KRAS-mutant non-small cell lung
cancer (NSCLC) and may differentially influence patient outcomes. We sought to …
[HTML] nih.gov

[HTML][HTML] Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes

JV Aredo, SK Padda, CA Kunder, SS Han… - Lung cancer …, 2019 - ncbi.nlm.nih.gov
Objectives: Concurrent genetic mutations are prevalent in KRAS-mutant non-small cell lung
cancer (NSCLC) and may differentially influence patient outcomes. We sought to …

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes

JV Aredo, SK Padda, CA Kunder… - Lung cancer …, 2019 - pubmed.ncbi.nlm.nih.gov
Objectives Concurrent genetic mutations are prevalent in KRAS-mutant non-small cell lung
cancer (NSCLC) and may differentially influence patient outcomes. We sought to …